Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

• Status: Recruiting
• Trial end date: 2025-12-31

Summary

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Collaborator: Children's Oncology Group
• Treatments: Glycine; Ivosidenib